Perspectives and experiences with COVID-19 vaccines in people with MS

John R. Ciotti1, Dana C. Perantie1, Brandon P. Moss2, Kathryn C. Fitzgerald3, Jeffrey A. Cohen2, Ellen M. Mowry3, Robert T. Naismith1, and Salim Chahin1

Abstract

Background: People with MS may have unique perspectives on COVID-19 vaccines due to their condition and/or medications.

Objective: Assess perspectives and experiences with COVID-19 vaccination, and quantify variables impacting COVID-19 vaccine willingness in people with MS.

Methods: A survey captured demographics, MS characteristics, and COVID-19 infection and exposures data; opinions on COVID-19 vaccine safety, side effects, and efficacy; and experiences following vaccination. Chi-square tests and a logistic regression model were used to denote between-group differences and variables predicting vaccine willingness, respectively.

Results: Most (87.8%) of the 237 participants were willing to receive the vaccine. Fifteen percent held or delayed a DMT dose for vaccination. MS symptoms worsened in a minority (7.6% first/only dose; 14.7% second dose), and most side effects were mild (80.0%; 55.3%). Those not planning to receive the vaccine were primarily concerned with long-term safety (70.4%). Medical comorbidities (adjusted odds ratio [aOR]=5.222; p=0.04) and following infection prevention precautions (aOR=6.330; p=0.008) were associated with vaccine willingness.

Conclusion: Most individuals with MS surveyed plan to receive the COVID-19 vaccine. People with MS experience similar side effects to the general population, and few experience transient MS symptom worsening. These results can inform conversations on vaccination between providers and people with MS.

Keywords: Multiple sclerosis, COVID-19, vaccine

Date received: 10 September 2021; accepted 16 February 2022
COVID-19 vaccines can also cause systemic side effects, such as fever, that can transiently worsen MS symptoms.\textsuperscript{15} COVID-19 vaccine safety in people with MS has been supported by expert organizations such as the National MS Society (NMSS) in the United States\textsuperscript{16} and internationally.\textsuperscript{17} Regarding vaccine efficacy, several studies have shown that some DMTs are associated with a reduced humoral immune response to existing vaccines,\textsuperscript{18,19} and emerging data suggest that this paradigm extends to the COVID-19 vaccines.\textsuperscript{20,21}

In this study, we first aim to evaluate the attitudes of people with MS towards the COVID-19 vaccines. We will additionally present the collective experiences of individuals within this cohort who have received at least one dose of a COVID-19 vaccine.

Methods
This is a prospective, observational, single-cohort study assessing patient-reported opinions and experiences with COVID-19 vaccines in people with MS. This project leverages data from the COVID-19 and Multiple Sclerosis survey-based registry at Washington University in St. Louis, Missouri, which was originally developed in collaboration with Cleveland Clinic and Johns Hopkins University. This study captures details from people with MS regarding their exposures to/experiences with COVID-19. This study is currently active, and over 300 participants are already enrolled. People with MS are invited to participate by verbal invitation at clinic visits, by telephone, or by messages through the electronic medical record. Participants in this study complete periodic surveys online: after completing a baseline survey, participants complete follow-up surveys every two weeks for the first three months, and monthly follow-up surveys thereafter for up to one year. Data are collected and managed using REDCap, a secure web-based software platform designed to support data capture for research studies.\textsuperscript{22,23} Enrollment in the registry began on September 17, 2020; a section of survey questions regarding COVID-19 vaccination was added to follow-up surveys on March 24, 2021. The data were censored on May 26, 2021.

All participants in the registry meeting the inclusion criteria were included in this analysis. Individual respondents were confirmed to be patients with a clinical diagnosis of MS followed at the tertiary care MS subspecialty outpatient clinic at Washington University, at which all people with MS are encouraged to get a COVID-19 vaccine when it is available to them in accordance with NMSS guidance.\textsuperscript{16}

Patient-level variables collected in this survey study include demographics; comorbidities applicable to COVID-19 such as hypertension, COPD, diabetes, and smoking status; employment status; MS characteristics such as subtype (per neurologist assessment in the medical record), date of last relapse, and which DMT they are treated with (as well as whether any alterations in dosing regimen were made); clinical information on any COVID-19 infection/exposures, if applicable; and behavioral modifications in response to the pandemic. Participants are also asked to report subjective and objective data on COVID-19 vaccines, such as whether they have received or are planning to receive the vaccine, whether they have concerns about vaccine safety/side effects/efficacy, and, if so, what those concerns are. If they have already received a COVID-19 vaccine, participants report the vaccine date/manufacturer, whether they experienced side effects or MS symptom worsening, what those side effects were, how long they lasted, and how severe they were.

Descriptive statistics are used to report COVID-19 vaccine perspectives and experiences of study participants. For some comparative analyses, respondents are categorized, such as those taking DMTs expected to have a large impact on humoral vaccine responses (i.e., B cell depleting monoclonal antibodies, sphingosine 1-phosphate [S1P] receptor modulators),\textsuperscript{19,24} denoted as “high-risk,” vs. DMTs expected to have a low impact, denoted as “low-risk;” those with and without medical comorbidities; and those with and without prior COVID-19 infection. Between-group comparisons of dichotomous categorical outcomes are analyzed using a chi-square test; where sample sizes are small, Fisher’s exact test is used instead. Between-group comparisons are presented alongside p-values to demonstrate statistical significance.

We also aimed to quantify the effects of gender, age, medical comorbidities, employment, history of COVID-19 infection, following infection prevention precautions, MS subtype, current DMT, and DMT changes on whether a participant will receive a COVID-19 vaccine. Univariate analyses are performed for each variable using a chi-square test as above. Relationships between independent variables and whether a participant will receive a COVID-19 vaccine are expressed as odds ratios and are presented alongside 95% confidence intervals and p-values. For
Table 1. Demographics.\(^a\)

| Parameter                                                                 | Value          |
|---------------------------------------------------------------------------|----------------|
| n                                                                         | 237            |
| Age, years - median (IQR)                                                 | 53.4 (43.7-63.0) |
| Female - no. (%)                                                          | 188 (79.3%)    |
| Pregnant/postpartum - no. (%)                                             | 1 (0.5%)       |
| Race/ethnicity - no. (%)                                                  |                |
| White                                                                     | 224 (94.5%)    |
| Black                                                                     | 10 (4.2%)      |
| Asian                                                                     | 2 (0.8%)       |
| Other                                                                     | 1 (0.4%)       |
| Ethnicity - no. (%)                                                       |                |
| Hispanic or Latino                                                        | 6 (2.5%)       |
| Comorbid medical conditions - no. (%)\(^c\)                               |                |
| 0                                                                         | 96 (40.5%)     |
| 1                                                                         | 92 (38.8%)     |
| 2 or more                                                                 | 49 (20.7%)     |
| MS subtype - no. (%)                                                      |                |
| RRMS                                                                      | 163 (68.8%)    |
| CIS                                                                       | 1 (0.4%)       |
| SPMS                                                                      | 50 (21.1%)     |
| PPMS                                                                      | 14 (5.9%)      |
| Unclear                                                                   | 9 (3.8%)       |
| Active disease - no. (%)\(^d\)                                           | 40 (16.9%)     |
| Current DMT - no. (%)\(^e\)                                              |                |
| Low-risk                                                                  | 88 (37.1%)     |
| High-risk                                                                 | 107 (45.1%)    |
| Untreated                                                                 | 41 (17.3%)     |
| Confirmed COVID infection - no. (%)\(^f\)                                 | 34 (14.3%)     |
| Required hospital admission/supplemental oxygen                          |                |
| Disposition                                                               | 2 (5.9%)       |
| Home                                                                      | 2 (100%)       |
| Skilled nursing facility/inpatient rehab                                  | 0 (0%)         |
| COVID infection outcome                                                   |                |
| Fully recovered                                                           | 18 (52.9%)     |
| Recovered with complications                                              | 11 (32.4%)     |
| Improving                                                                 | 4 (11.8%)      |
| Worsening                                                                 | 1 (2.9%)       |
| Social behaviors - no. (%)\(^g\)                                         |                |
| Social distancing (leaving home less than before pandemic)                | 206 (92.4%)    |
| Wearing a mask at least some of the time                                  | 218 (97.8%)    |
| Maintaining 6 feet of separation when out                                 | 211 (94.6%)    |

\(^a\)Percentages given reflect proportion responding to question.

\(^b\)Currently pregnant or had given birth in the past 6 weeks at time of baseline survey.

\(^c\)Including BMI >30, current smoker, chronic lung disease, heart disease, stroke, diabetes, hypertension, chronic liver disease, chronic kidney disease, cancer, history of organ transplant, HIV, and other systemic inflammatory disease.

\(^d\)Defined as at least one relapse in the 12 months preceding the baseline survey or during the survey period.

\(^e\)Low-risk DMT defined as interferons, glatiramer acetate, teriflunomide, fumarates. High-risk DMT defined as S1P receptor modulators, B cell depleting agents, cladribine, natalizumab, alemtuzumab.\(^7,19\)

\(^f\)Defined as positive COVID-19 test at any point.

\(^g\)At time of baseline survey.
multivariable analyses, a logistic regression model was developed and is also presented to assess these relationships. All tested variables are included in the model using forced entry. These relationships are expressed as adjusted odds ratios, and are also shown alongside 95% confidence intervals and p-values.

### Results

Approximately 1700 patients were invited to participate in the study via direct messaging in the electronic medical record, phone calls, and/or written fliers in clinic in which 311 responded (≈18% response rate, though it is unknown how many recipients of the electronic invitation actually accessed it). Quality control checks confirmed respondents were followed at our center with a diagnosis of MS. Of the baseline survey respondents, 237 (76.2%) had responded to a follow-up survey including questions on COVID-19 vaccination, comprising this study’s overall sample. More than half of these participants had completed a follow-up survey at 8 months following their initial baseline survey (interquartile range [IQR]: Month 5 – Month 8).

Study sample demographics are presented in Table 1. This cohort had an average age of 53.4 years, was predominantly female (79.3%), and was predominantly white (94.5%). All subtypes of MS were represented, and 16.9% had active disease (at least one relapse in the 12 months preceding the baseline survey or at any point during the survey period). There was a high incidence of confirmed COVID-19 infection in the study cohort (14.3%), though few required inpatient admission, and more than half (52.9%) fully recovered. More than 90% of respondents followed general infection prevention precautions at the time of their baseline survey response, including social distancing (92.4%), wearing a mask at least some of the time (97.8%), and maintaining 6 feet of separation when out (94.6%).

Within this sample of people with MS, the vast majority (87.8%) either received or were planning to receive a COVID-19 vaccine (Table 2); only 8.0% were not planning to receive a COVID-19 vaccine, and the remainder (4.2%) were unsure. Compared to those who received or were planning to receive the vaccine, those who were not planning to receive or were unsure about receiving the vaccine were significantly less likely to be worried about being at greater risk of catching COVID-19 (58.2% received/planning to receive vs. 31.0% not planning/unsure; p=0.004) or suffering more complications from COVID-19 infection (73.7% vs. 31.0%; p<0.001). Conversely, those who were not planning to receive the vaccine were more worried about MS worsening than COVID-19 (50.0% vs. 69.0%; p=0.03), and more wary of vaccine safety/side effects (34.1% vs. 93.1%; p<0.001). The primary concern among those not planning to receive the vaccine was its long-term safety (38.0% vs. 70.4%; p=0.004). Concerns about vaccine efficacy due to a participant’s DMT were more common in those who received or were planning to receive the vaccine (37.8% vs. 20.7%; p=0.001).

Of those who had already received a COVID-19 vaccine (Table 3), the majority received mRNA vaccines (57.7% Pfizer-BioNTech, 34.6% Moderna), and of those, more than 90% had completed the two-dose series. 15.0% held or delayed a dose of their DMT for vaccination, the majority of whom were on high efficacy drugs (41.7% ocrelizumab, 16.7% natalizumab). Some participants felt that their MS symptoms worsened after their first/only (7.6%) or second (14.7%) doses. Side effects from the injections were common (76.1% first/only dose, 82.7% second dose) but short-lived, with a median of 2 days duration following either dose. Most side effects were mild (80.0% first/only dose, 55.3% second dose); side effects preventing participants from performing their usual activities were uncommon (1.3% first/only dose, 17.7% second dose).

Univariate odds ratios and adjusted odds ratios from the logistic regression model are presented in Table 4. Low numbers of minority respondents and those who had changed their DMT dosing/frequency precluded these variables from inclusion in the model; all patients in these categories received or planned to receive a COVID-19 vaccine. After adjusting for the other variables listed in Table 4, having 2 or more medical comorbidities predisposing to worse COVID-19 outcomes was associated with 5.2-fold greater odds of receiving a vaccine (adjusted odds ratio [aOR]=5.2; p=0.04; 95% confidence interval [CI]: 1.1 to 25.7). With the same adjustments, following recommended infection prevention precautions was associated with 6.3-fold greater odds of receiving a COVID-19 vaccine (aOR=6.3; p=0.008; 95% CI: 1.6 to 24.9). Having untreated MS was associated with significantly lower adjusted odds of receiving a vaccine (aOR=0.1; p=0.003; 95% CI: 0.0 to 0.4). Female sex (aOR=3.4; p=0.06; 95% CI: 1.0 to 11.6) and a progressive MS subtype (aOR=5.3; p=0.05; 95% CI: 1.0 to 29.0) trended towards a higher likelihood of getting a vaccine,
| Table 2. Attitudes towards COVID-19 and vaccination.\textsuperscript{a} |
|---------------------------------------------------------------|
| \textbf{n} | Received/planning to receive COVID-19 vaccine - no. (%) | Not planning to receive COVID-19 vaccine - no. (%) | p-value |
|---------------------------------------------------------------|
| 237 | 208 | 29 | |
| 87.8% | (87.8%) | | |
| 8.0% | 19 (8.0%) | | <0.001 |
| 4.2% | 10 (4.2%) | | 0.765 |
| Total | | | |
| 237 | 208 | 29 | |
| Worried about being at greater risk of COVID-19 due to MS and/or DMT - no. (%) | 130 | 121 (58.2%) | 0.004 |
| (57.5%) | | | |
| Worried about having more complications from COVID-19 due to MS and/or DMT - no. (%) | 155 | 146 (73.7%) | <0.001 |
| (68.6%) | | | |
| Switched/stopped DMTs specifically to prevent COVID-19 - no. (%) | 5 (2.1%) | 4 (1.9%) | 0.765 |
| More worried about MS worsening than risk of COVID-19 - no. (%) | 119 | 99 (50.0%) | 0.034 |
| (52.7%) | | (69.0%) | |
| No concerns about COVID-19 vaccine safety/side effects - no. (%) | 139 | 137 (65.9%) | <0.001 |
| (58.6%) | | (6.9%) | |
| Concerns about COVID-19 vaccine safety/side effects... - no. (%)\textsuperscript{c} | 98 | 71 (34.1%) | <0.001 |
| (41.4%) | | (93.1%) | |
| because I have MS | 46 | 34 (47.9%) | 0.760 |
| (46.9%) | | (44.4%) | |
| because of my DMT | 32 | 26 (36.6%) | 0.174 |
| (32.7%) | | (22.2%) | |
| about short-term side effects | 31 | 25 (35.2%) | 0.217 |
| (31.6%) | | (22.2%) | |
| about long-term safety | 46 | 27 (38.0%) | 0.004 |
| (46.9%) | | (70.4%) | |
| about a possible allergy to vaccine or its components | 6 (6.1%) | 3 (4.2%) | 0.342 |
| other concerns | 7 (7.1%) | 2 (2.8%) | 0.016 |
| Concerns about COVID-19 vaccine effectiveness because of DMT - no. (%)\textsuperscript{d} | 74 | 68 (37.8%) | 0.001 |
| (37.4%) | | (20.7%) | |

\textsuperscript{a}Percentages given reflect proportion responding to question.
\textsuperscript{b}Includes those not planning to receive vaccine or unsure about receiving vaccine.
\textsuperscript{c}Participants able to give more than one answer; percentages may not add to 100%.
\textsuperscript{d}Among those currently on a disease-modifying therapy.
but were not statistically significant in the final adjusted model.

**Discussion**

In this observational survey of people with MS, we found that the vast majority of respondents have received or are planning to receive the COVID-19 vaccine. More people with MS in our survey were concerned about being at a greater risk for COVID-19 due to MS/DMT than safety and side effects of the vaccine. Transient worsening of MS symptoms was more common after the second dose (for two-dose vaccines), but was only reported by 15% of participants. As in the general population, side effects to the vaccine were relatively common, but the majority were mild and short-lived. Participants who were concerned about being at higher risk for COVID-19 (either due to other comorbidities or being on a DMT) and those who followed infection prevention precautions at the time of the baseline survey were more willing to get the vaccine. Less than 40% of participants were concerned about vaccine effectiveness because of their DMT, though many of the survey responses were recorded before recent publications on the impact of DMTs and other immunosuppressive medications on COVID-19 vaccine efficacy.\(^{20,21}\)

Vaccine hesitancy threatens the progress that has been made in combating the COVID-19 pandemic in the United States. Vaccine willingness questions in this study were answered on follow-up surveys administered between March and May of 2021. It is encouraging to see that 87.8% of participants in this study are willing to receive one of these vaccines. Other studies of COVID-19 vaccine willingness in people with MS,\(^{11}\) though many of the survey responses were recorded before recent publications, found that the vast majority of respondents have received or are planning to receive the COVID-19 vaccine. More people with MS in our survey were concerned about being at a greater risk for COVID-19 due to MS/DMT than safety and side effects of the vaccine. Transient worsening of MS symptoms was more common after the second dose (for two-dose vaccines), but was only reported by 15% of participants. As in the general population, side effects to the vaccine were relatively common, but the majority were mild and short-lived. Participants who were concerned about being at higher risk for COVID-19 (either due to other comorbidities or being on a DMT) and those who followed infection prevention precautions at the time of the baseline survey were more willing to get the vaccine. Less than 40% of participants were concerned about vaccine effectiveness because of their DMT, though many of the survey responses were recorded before recent publications on the impact of DMTs and other immunosuppressive medications on COVID-19 vaccine efficacy.\(^{20,21}\)

Reported concerns regarding COVID-19 vaccination and MS suggest an important and ongoing role for improved patient education. Vaccine safety has been the predominant concern in prior studies of COVID-19 vaccine perspectives amongst people with MS,\(^{11}\) and substantial minorities of participants in this study report concerns over vaccine safety and/or side effects, despite agreement amongst professional organizations that COVID-19 vaccines are safe for people with MS and safe to use with DMTs.\(^{16,17}\) Systemic side effects such as pain at the injection site, fatigue, headaches, and myalgias following COVID-19 vaccination are relatively common in this cohort and are similar to those observed in the general population, including in terms of duration and severity.\(^{28,29}\) Furthermore, only 15% of participants experienced transient worsening of their MS symptoms following vaccination, which should reassure people who have concerns about how the COVID-19 vaccine may exacerbate their symptoms. Messaging targeting those remaining unvaccinated should focus on vaccine safety, and the short duration of predominantly mild side effects observed in this study may additionally lessen the degree of perceived vaccination risk amongst this group.

Some DMTs can diminish humoral immune responses to COVID-19 vaccination,\(^{20}\) which may leave some vaccinated individuals under-protected or unprotected against COVID-19. However, in this study, fewer participants expressed concern that their DMT could reduce the vaccine’s effectiveness than the number taking a high-risk DMT. Of the 58 participants taking a B cell depleting therapy (ocrelizumab, ofatumumab, or rituximab), 10 (17.2%) reported an adjustment in their dosing regime (e.g., holding or delaying an infusion or injection). Though there is a mechanistic rationale for holding a B cell depleting agent to allow B cells to repopulate prior to vaccination, clinical evidence to support this strategy is lacking,\(^{20}\) and future studies evaluating both humoral and cellular immune responses in people with MS on varying degrees of B cell
depleting therapy, both in terms of duration from last infusion and total time on drug, are sorely needed. Several respondents also made adjustments in their dosing regimen of interferons, which should not impact the response to COVID-19 vaccination; this may reflect personal patient concerns over getting multiple injections or “stacking” of flu-like side effects from both their DMT and the COVID-19 vaccine. Decisions on whether to hold or delay a DMT dose should be made by an experienced physician, should be individualized, and should take into consideration the individual’s clinical characteristics as well as their risk of COVID-19 infection. Outstanding questions on the effects of DMTs on COVID-19 vaccine efficacy provide another opportunity for patient education and counseling on the importance of continuing to follow standard infection prevention precautions, even after vaccination, especially if treated with a cell-depleting medication such as ocrelizumab, ofatumumab, or alemtuzumab, or an S1P receptor modulator (fingolimod, siponimod, ozanimod, ponesimod).

Table 3. Experiences with COVID-19 vaccination.

| Manufacturer - no. (%) | Pfizer-BioNTech 120 (57.7%) |
|------------------------|-------------------------------|
| Received both doses    | 113 (95.0%)                   |
| Days between doses - mean (SD) | 21.5 (3.7) |
| Moderna                | 72 (34.6%)                    |
| Received both doses    | 65 (90.3%)                    |
| Days between doses - mean (SD) | 29.5 (3.7) |
| Johnson & Johnson      | 9 (4.3%)                      |
| Unsure/no response     | 7 (3.7%)                      |
| Held/delayed DMT dose for the vaccine - no. (%)a | 24 (15.0%) |
| Interferons            | 10 (41.7%)                    |
| Ocrelizumab            | 10 (41.7%)                    |
| Natalizumab            | 4 (16.7%)                     |

| MS symptom worsening after vaccination - no. (%) | After first doseb |
|-------------------------------------------------|------------------|
| No vaccine side effects - no. (%)               | 15 (7.6%)        |
| Pain in the arm at injection site               | 144 (71.6%)      |
| Swelling in the arm at injection site           | 19 (9.5%)        |
| Fever                                           | 9 (4.5%)         |
| Chills                                          | 11 (5.5%)        |
| Tiredness                                       | 60 (29.9%)       |
| Headache                                        | 38 (18.9%)       |
| Muscle aches                                    | 27 (13.4%)       |
| Lightheadedness                                 | 4 (2.0%)         |
| Rash                                            | 2 (1.0%)         |
| Nausea/vomiting                                 | 144 (71.6%)      |
| Diarrhea                                        | 19 (9.5%)        |
| Swollen or sore lymph nodes                     | 9 (4.5%)         |
| Allergic reaction                               | 11 (5.5%)        |
| Other                                           | 6 (3.0%)         |
| Duration of side effects, days - median (IQR)   | 2 (1-3)          |
| Severity of side effects - no. (%)              | 2 (1-3)          |

| aAmong those currently on a disease-modifying therapy. |
| bFirst dose of mRNA vaccine, or single dose of other vaccines. |
Table 4. Univariate and adjusted odds ratios for receiving or planning to receive COVID-19 vaccine.

|                          | Univariate | 95% CI     | P-value | Adjusted | 95% CI     | P-value |
|--------------------------|------------|------------|---------|----------|------------|---------|
| **Sex**                  |            |            |         |          |            |         |
| Male                     | †          |            |         |          | †          |         |
| Female                   | 3.262      | 1.437-7.407| 0.005   |          | 3.355      | 0.975-11.551| 0.055   |
| **Age**                  |            |            |         |          |            |         |
| Under 60 years old       | †          |            |         | †        |            |         |
| 60+ years old            | 2.162      | 0.843-5.545| 0.109   |          | 1.261      | 0.324-4.905| 0.737   |
| **Medical comorbidities**|            |            |         |          |            |         |
| 0                        | †          |            |         | †        |            |         |
| 1                        | 1.138      | 0.496-2.611| 0.760   |          | 2.205      | 0.706-6.880| 0.173   |
| 2 or more                | 2.618      | 0.715-9.588| 0.146   |          | 5.222      | 1.061-25.693| 0.042   |
| **Employment**           |            |            |         |          |            |         |
| Standard risk employment | †          |            |         | †        |            |         |
| High risk employment     | 0.726      | 0.238-2.211| 0.573   |          | 0.703      | 0.175-2.828| 0.620   |
| Loss of employment during pandemic | 1.517 | 0.277-8.310| 0.631   |          | 0.803      | 0.121-5.316| 0.820   |
| Not employed prior to during pandemic | 2.933 | 0.951-9.050| 0.061   |          | 0.939      | 0.237-3.720| 0.929   |
| **Confirmed COVID-19 infection** |            |            |         |          |            |         |
| No                       | †          |            |         | †        |            |         |
| Yes                      | 0.778      | 0.275-2.201| 0.636   |          | 0.875      | 0.204-3.744| 0.857   |
| **Following infection prevention precautions** |            |            |         |          |            |         |
| No                       | †          |            |         | †        |            |         |
| Yes                      | 12.545     | 4.782-32.914| <0.001 |          | 6.330      | 1.610-24.894| 0.008 |
| **MS subtype**           |            |            |         |          |            |         |
| Relapsing MS (CIS, RRMS) | †          |            |         | †        |            |         |
| Progressive MS (SPMS, PPMS) | 3.831 | 1.117-13.139| 0.033   |          | 5.338      | 0.983-28.994| 0.052   |
| **Current DMT**          |            |            |         |          |            |         |
| Low-risk                 | †          |            |         | †        |            |         |
| High-risk                | 1.396      | 0.541-3.604| 0.491   |          | 0.706      | 0.201-2.481| 0.587   |
| Untreated                | 0.456      | 0.169-1.227| 0.120   |          | 0.096      | 0.021-0.444| 0.003   |
| Stopped/switched DMT during pandemic |                  |        |         |          |            |         |
| No                       | †          |            |         | †        |            |         |

(continued)
Numerous interrelated variables play a role in one’s decision on whether to receive the COVID-19 vaccine. In this cohort, both following infection prevention precautions and having medical comorbidities are associated with a willingness to get the vaccine, which suggests a cohort that is more likely to follow health authority guidelines and medical advice, and that understands the importance of protective measures and their own degree of risk. Conversely, and potentially reflecting history of adverse responses or skepticism of medical advice, being untreated is associated with not receiving the vaccine, even after adjusting for age (those who are elderly may be less likely to be on a DMT, but trended towards receiving the vaccine in the univariate analysis) and other variables. Gender trended towards being a significant predictor of vaccine willingness in the adjusted model, consistent with the general population in the United States. 

Prior studies have similarly shown race to be a significant predictor of COVID-19 vaccine willingness in the general population, but low numbers of minority respondents prevented their inclusion in this regression model. It is notable that minority respondents (10 Black, 2 Asian, and 1 other) all received or plan to receive the COVID-19 vaccine.

This study is not without limitations. Survey response bias may have influenced multiple variables, including willingness to vaccinate, the proportions of participants with a prior confirmed COVID-19 infection (e.g., may be more invested in contributing to research on this subject), those with favorable outcomes from those infections (e.g., those with a poor outcome who otherwise would have participated may not be capable of doing so), and demographics (as this sample skews older). The relatively low response rate limits the generalizability of the study. Respondents to the electronic survey invitation may have skewed more technologically savvy or more engaged in their care. These data were collected from patients followed at a single center in St. Louis, Missouri that sees few, if any, uninsured or state-sponsored insured patients, which may skew unmeasured variables such as socioeconomic status and also limit the external validity of the study. Disability data were also not collected in this study, which may be associated with the dependent variable (vaccine willingness) as well as several independent variables (risk of COVID-19, age, DMT, employment). Future studies should dig deeper into why patients chose to hold or change their DMT for the COVID-19 vaccine and compare COVID-19 vaccine willingness to willingness to receive other childhood or travel-related vaccines.

### Conclusions

Most people with MS who responded to our survey, notably those who consider themselves at high risk for COVID-19, were willing to receive a vaccine. Vaccine side effects in people with MS were similar to the general population, but low numbers of minority respondents prevented their inclusion in this regression model. It is notable that minority respondents (10 Black, 2 Asian, and 1 other) all received or plan to receive the COVID-19 vaccine.

### Declaration of Competing Interests

J.R.C. reports consulting fees from EMD Serono and Genentech, and grant funding from the National Multiple Sclerosis Society, all outside the submitted work. D.C.P. reports no competing interests. B.P.M. reports consulting fees from Biogen and stock in

### Table 4. Continued.

|                | Univariate OR | 95% CI      | P-value | Adjusted OR | 95% CI      | P-value |
|----------------|---------------|-------------|---------|-------------|-------------|---------|
| Yes            | 1.039         | 0.372-2.900 | 0.942   | 0.977       | 0.271-3.527 | 0.972   |

[a]Including BMI >30, current smoker, chronic lung disease, heart disease, stroke, diabetes, hypertension, chronic liver disease, chronic kidney disease, cancer, history of organ transplant, HIV, and other systemic inflammatory disease.

[1]Defined as active healthcare worker (e.g. nurse, technician, physician, hospital worker), active first-line responder (e.g. police, firefighter, paramedic), active essential worker (e.g. grocery store), or active worker in shelter or prison.

[2]Defined as positive COVID-19 test at any point.

[3]Defined as social distancing (leaving home less than before the pandemic), wearing a mask at least some of the time, and maintaining 6 feet of separation when out.

[4]Referrant.
Pfizer, and has received grant funding from Genentech, all outside the submitted work. K.C.F. reports no competing interests. J.A.C. reports personal compensation for consulting for Biogen, Bristol-Myers Squibb, Convelo, Genentech, Janssen, NervGen, Novartis, and PSI; speaking for H3 Communications; and serving as an Editor of *Multiple Sclerosis Journal*. E.M.M. reports serving as PI or site PI for studies sponsored by Biogen and Genentech, and receiving free medication for a clinical trial, of which she is PI, from Teva, as well as royalties for editorial duties from UpToDate. R.T.N. reports consulting fees for Banner Life Sciences, Biogen, Bristol Myers Squibb, Genentech, Genzyme, Janssen, GW Therapeutics, Horizon Therapeutics, Lundbeck, NervGen, TG Therapeutics, Third Rock Ventures, and Viela Bio, all outside the submitted work. S.C. reports grant funding from Biogen (partially supporting this work), and consulting and/or speaking fees from Biogen, Genentech, Genzyme and Novartis, all outside the submitted work.

**Funding**

This work is partially supported by a sponsored research agreement from Biogen and the Leon and Harriet Felman Fund for Human MS Research.

**ORCID iDs**

John R. Ciotti [https://orcid.org/0000-0002-5696-8841](https://orcid.org/0000-0002-5696-8841)

Dana C. Perantie [https://orcid.org/0000-0002-6380-8133](https://orcid.org/0000-0002-6380-8133)

Brandon P. Moss [https://orcid.org/0000-0001-5319-5129](https://orcid.org/0000-0001-5319-5129)

Kathryn C. Fitzgerald [https://orcid.org/0000-0003-3137-0322](https://orcid.org/0000-0003-3137-0322)

Jeffrey A. Cohen [https://orcid.org/0000-0001-9245-9772](https://orcid.org/0000-0001-9245-9772)

**References**

1. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. *Neurology* 2019; 92(10): e1029–e40.
2. Dobson R and Giovannoni G. Multiple sclerosis – a review. *Eur J Neurol* 2019; 26(1): 27–40.
3. Comi G, Radaelli M and Soelberg Sorensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. *Lancet* 2017; 389(10076): 1347–56.
4. Brownlee W, Bourdette D, Broadley S, Killestein J and Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. *Neurology* 2020; 10.1212/WNL.00000.
5. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E and Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. *Mult Scler Relat Disord* 2020; 39: 102073.
6. Willis MD and Robertson NP. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. *J Neurol* 2020; 267(5): 1567–9.
7. Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. *JAMA Neurol* 2021; 78(6): 699–708.
8. Fitzgerald KC, Mecoli CA, Douglas M, Harris S, Aravidis B, Albaya J, et al. Risk factors for infection and health impacts of the covid-19 pandemic in people with autoimmune diseases. *Clin Infect Dis* 2021; ciab407.
9. Sormani MP, De Rossi N, Schiavietti I, Carmisciano L, Cordioli C, Moiola L, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. *Ann Neurol* 2021; 89: 780–9.
10. Rosenbaum L. Escaping catch-22 – overconing covid vaccine hesitancy. *N Engl J Med* 2021; 384(14): 1367–1371. doi: 10.1056/NEJMcms2101220.
11. Xiang XM, Hollen C, Yang Q, Brumbach BH, Spain RI and Wooliscroft L. COVID-19 vaccination willingness among people with multiple sclerosis. *Mult Scler J Exp Transl Clin* 2021; 7(2): 20552173211017159.
12. Langer-Gould A, Qian L, Tartof SY, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. *JAMA Neurol* 2014; 71(12): 1506–1513. doi: 10.1001/jamaneurol.2014.2633.
13. Maitland MT and Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. *J Neurol* 2017; 264(6): 1035–1050. doi: 10.1007/s00415-016-8263-4.
14. Ehde D, Roberts MK, Herring TE and Alschuler KN. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States. *Mult Scler Relat Disord* 2021; 49: 102788. doi: 10.1016/j.msard.2021.102788.
15. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID vaccine. *Eur J Neurol* 2020; 27(5): 1049–56. doi: 10.1111/ene.14035.
16. National MS Society. COVID-19 Vaccine Guidance for People Living with MS. https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance. (Access 05/10/21).
17. MS International Federation. MS, the coronavirus and the use of MS disease-modifying therapies. *J Neurol* 2020; 267(5): 1347–56.
18. Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocresolimus in vaccine
responses in patients with multiple sclerosis: the VELOCE study. Neurology 2020; 95(14): e1999–e2008.

19. Ciotti JR, Valtecheva MV and Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord 2020; 45: 102439.

20. Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler 2021; 27(6): 864–870. doi: 10.1177/13524585211003476.

21. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv 2021; 2021.04.05.21254656.

22. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N and Conde JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42(2): 377–81.

23. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software partners. J Biomed Inform 2019. doi: 10.1016/j.jbi.2019.103208.

24. Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology 2021; 97(19): e1870–e1885. doi: 10.1212/WNL.0000000000012753.

25. Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. COVID-19 outcomes in MS: Observational study of early experience from NYU multiple sclerosis comprehensive care center. Neurol Neuroimmunol Neuroinflamm 2020; 7(5): e835.

26. Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 2020; 77(9): 1079–1088.

27. Mateen FJ, Rezaei S, Alakel N, Gazdag B, Kumar AR and Vogel A. Impact of COVID-19 on U.S. and Canadian neurologists’ therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices. J Neurol 2020; 267(12): 3467–3475.

28. Meo SA, Bukhari IA, Akram J, Meo AS and Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci 2021; 25(3): 1663–1669.

29. Riad A, Pokorná A, Attia S, Klugarová J, Koščík M and Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med 2021; 10(7): 1428.

30. COVID Data Tracker. Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United States. https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic. (Access 06/25/21).

31. Salmon DA, Dudley MZ, Brewer J, Kan L, Gerber JE, Budigan H, et al. COVID-19 vaccination attitudes, values and intentions among United States adults prior to emergency use authorization. Vaccine 2021; 39(19): 2698–2711.

32. Bajaj SS and Stanford SC. Beyond tuskegee — vaccine distrust and everyday racism. N Engl J Med 2021; 384: e12.